- Locally advanced or metastatic disease that can be measured. Patients with bone-only
disease are also allowed to enter the study.
- Previous treatment with an anthracycline and a taxane in any setting
- Progression on first or second line regimen or adjuvant regimen if disease free
interval less than 12 months
- History of inflammatory carcinoma if there is no other measurable disease
- More than 2 chemotherapy agents in the advanced disease setting
- Brain metastases